Dyne Therapeutics, Inc. (NASDAQ:DYN) Expected to Post FY2024 Earnings of ($2.87) Per Share

Dyne Therapeutics, Inc. (NASDAQ:DYN) – Chardan Capital issued their FY2024 earnings per share estimates for Dyne Therapeutics in a report released on Monday, May 6th. Chardan Capital analyst K. Nakae forecasts that the company will post earnings per share of ($2.87) for the year. Chardan Capital has a “Buy” rating and a $31.00 price objective on the stock. The consensus estimate for Dyne Therapeutics’ current full-year earnings is ($3.27) per share.

Other research analysts also recently issued reports about the company. HC Wainwright reaffirmed a “buy” rating and set a $36.00 target price on shares of Dyne Therapeutics in a report on Friday, May 3rd. Stifel Nicolaus boosted their target price on shares of Dyne Therapeutics from $35.00 to $41.00 and gave the company a “buy” rating in a report on Wednesday, March 6th. Morgan Stanley began coverage on Dyne Therapeutics in a report on Tuesday, April 30th. They set an “overweight” rating and a $40.00 price target for the company. Oppenheimer reissued an “outperform” rating and issued a $47.00 price objective on shares of Dyne Therapeutics in a research note on Monday. Finally, Piper Sandler lifted their target price on Dyne Therapeutics from $27.00 to $29.00 and gave the stock an “overweight” rating in a report on Wednesday, March 6th. One analyst has rated the stock with a sell rating, seven have assigned a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, Dyne Therapeutics presently has an average rating of “Moderate Buy” and a consensus price target of $37.75.

Dyne Therapeutics Stock Performance

DYN stock opened at $25.69 on Thursday. The company has a market capitalization of $2.24 billion, a P/E ratio of -6.47 and a beta of 1.00. The company has a fifty day moving average price of $26.49 and a 200-day moving average price of $18.88. Dyne Therapeutics has a 52-week low of $6.40 and a 52-week high of $30.27.

Dyne Therapeutics (NASDAQ:DYN) last issued its quarterly earnings data on Tuesday, March 5th. The company reported ($1.09) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.92) by ($0.17).

Insider Buying and Selling

In other news, insider Wildon Farwell sold 5,493 shares of the stock in a transaction that occurred on Monday, February 12th. The shares were sold at an average price of $25.07, for a total transaction of $137,709.51. Following the completion of the transaction, the insider now directly owns 163,503 shares of the company’s stock, valued at approximately $4,099,020.21. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other Dyne Therapeutics news, Director Jason P. Rhodes sold 248,219 shares of the firm’s stock in a transaction dated Monday, February 26th. The stock was sold at an average price of $23.72, for a total value of $5,887,754.68. Following the completion of the transaction, the director now owns 903,527 shares in the company, valued at approximately $21,431,660.44. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, insider Wildon Farwell sold 5,493 shares of Dyne Therapeutics stock in a transaction dated Monday, February 12th. The shares were sold at an average price of $25.07, for a total value of $137,709.51. Following the transaction, the insider now directly owns 163,503 shares of the company’s stock, valued at approximately $4,099,020.21. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 1,875,432 shares of company stock valued at $44,368,530. 20.77% of the stock is owned by insiders.

Institutional Investors Weigh In On Dyne Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of the company. Fcpm Iii Services B.V. purchased a new position in Dyne Therapeutics during the fourth quarter valued at approximately $81,543,000. Braidwell LP lifted its stake in Dyne Therapeutics by 32.2% in the 3rd quarter. Braidwell LP now owns 1,821,972 shares of the company’s stock worth $16,325,000 after purchasing an additional 444,100 shares in the last quarter. Vivo Capital LLC boosted its holdings in Dyne Therapeutics by 58.0% in the 1st quarter. Vivo Capital LLC now owns 1,635,136 shares of the company’s stock valued at $46,422,000 after purchasing an additional 600,000 shares during the period. Jennison Associates LLC grew its position in shares of Dyne Therapeutics by 495.2% during the 1st quarter. Jennison Associates LLC now owns 1,207,551 shares of the company’s stock valued at $34,282,000 after purchasing an additional 1,004,680 shares in the last quarter. Finally, Armistice Capital LLC increased its holdings in shares of Dyne Therapeutics by 31.6% in the third quarter. Armistice Capital LLC now owns 1,200,000 shares of the company’s stock worth $10,752,000 after purchasing an additional 288,000 shares during the period. 96.68% of the stock is owned by hedge funds and other institutional investors.

About Dyne Therapeutics

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.